company background image
XRTX

XORTX Therapeutics TSXV:XRTX Stock Report

Last Price

CA$0.78

Market Cap

CA$11.2m

7D

-19.6%

1Y

-64.7%

Updated

31 Jan, 2023

Data

Company Financials +

XRTX Stock Overview

XORTX Therapeutics Inc., a bio-pharmaceutical company, engages in the development and commercialization of therapies to treat progressive kidney diseases, diabetes, insulin resistance, metabolic syndrome, diabetes, diabetic nephropathy, and infection.

XRTX fundamental analysis
Snowflake Score
Valuation2/6
Future Growth0/6
Past Performance4/6
Financial Health6/6
Dividends0/6

My Notes

New

Notes are coming soon

XORTX Therapeutics Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for XORTX Therapeutics
Historical stock prices
Current Share PriceCA$0.78
52 Week HighCA$3.00
52 Week LowCA$0.78
Beta0.32
1 Month Change-30.36%
3 Month Change-30.36%
1 Year Change-64.71%
3 Year Change-52.54%
5 Year Change-80.74%
Change since IPO-86.71%

Recent News & Updates

Recent updates

Here's Why We're Watching XORTX Therapeutics' (CVE:XRTX) Cash Burn Situation

Aug 23
Here's Why We're Watching XORTX Therapeutics' (CVE:XRTX) Cash Burn Situation

XORTX Therapeutics (CVE:XRTX) Is In A Strong Position To Grow Its Business

Apr 01
XORTX Therapeutics (CVE:XRTX) Is In A Strong Position To Grow Its Business

We're Interested To See How XORTX Therapeutics (CVE:XRTX) Uses Its Cash Hoard To Grow

Dec 16
We're Interested To See How XORTX Therapeutics (CVE:XRTX) Uses Its Cash Hoard To Grow

Companies Like XORTX Therapeutics (CSE:XRX) Can Afford To Invest In Growth

Sep 01
Companies Like XORTX Therapeutics (CSE:XRX) Can Afford To Invest In Growth

Shareholder Returns

XRTXCA PharmaceuticalsCA Market
7D-19.6%-3.7%0.6%
1Y-64.7%-59.1%-0.6%

Return vs Industry: XRTX underperformed the Canadian Pharmaceuticals industry which returned -59.1% over the past year.

Return vs Market: XRTX underperformed the Canadian Market which returned -0.6% over the past year.

Price Volatility

Is XRTX's price volatile compared to industry and market?
XRTX volatility
XRTX Average Weekly Movement16.2%
Pharmaceuticals Industry Average Movement14.2%
Market Average Movement9.9%
10% most volatile stocks in CA Market19.1%
10% least volatile stocks in CA Market3.9%

Stable Share Price: XRTX is more volatile than 75% of Canadian stocks over the past 3 months, typically moving +/- 16% a week.

Volatility Over Time: XRTX's weekly volatility (16%) has been stable over the past year, but is still higher than 75% of Canadian stocks.

About the Company

FoundedEmployeesCEOWebsite
n/an/aAllen Davidoffhttps://www.xortx.com

XORTX Therapeutics Inc., a bio-pharmaceutical company, engages in the development and commercialization of therapies to treat progressive kidney diseases, diabetes, insulin resistance, metabolic syndrome, diabetes, diabetic nephropathy, and infection. It develops XRx-008, a late clinical stage program therapy for autosomal dominant polycystic kidney disease; XRx-101, an uric acid lowering agent used to treat patients infected with the coronavirus COVID-19 infection and suppression of acute kidney injury and associated health consequences; and XRx-221, a xanthine oxidase inhibitor candidates for the treatment of diabetic nephropathy. The company has a partnership with the Icahn School of Medicine to study the incidence of acute kidney injury and hyperuricemia in patients hospitalized with COVID-19.

XORTX Therapeutics Inc. Fundamentals Summary

How do XORTX Therapeutics's earnings and revenue compare to its market cap?
XRTX fundamental statistics
Market CapCA$11.22m
Earnings (TTM)CA$2.53m
Revenue (TTM)n/a

4.4x

P/E Ratio

0.0x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
XRTX income statement (TTM)
RevenueCA$0
Cost of RevenueCA$0
Gross ProfitCA$0
Other Expenses-CA$2.53m
EarningsCA$2.53m

Last Reported Earnings

Sep 30, 2022

Next Earnings Date

n/a

Earnings per share (EPS)0.18
Gross Margin0.00%
Net Profit Margin0.00%
Debt/Equity Ratio0%

How did XRTX perform over the long term?

See historical performance and comparison